| Professional Services Industry | Industrials Sector | Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D. CEO | XDUS Exchange | CNE1000040M1 ISIN |
| DE Country | 10,185 Employees | 18 Jun 2026 Last Dividend | - Last Split | - IPO Date |
Hangzhou Tigermed Consulting Co., Ltd, established in 2004 and headquartered in Hangzhou, the People's Republic of China, stands as a significant player providing contract research organization services both domestically and internationally. The company's operations are held across two primary segments: Clinical Trial Solutions and Clinical-related and Laboratory Services. Through these segments, Tigermed extends a comprehensive suite of services covering a wide spectrum of the pharmaceutical and medical research domain, including preclinical and clinical development, clinical-related services, and extensive laboratory services. With its extensive portfolio, Tigermed aims to support the development, testing, and regulatory compliance of pharmaceuticals and medical devices globally.
Preclinical services provided by Tigermed include medicinal chemistry for drug discovery, compound screening for potential efficacy, DMPK (Drug Metabolism and Pharmacokinetics) studies, safety and toxicology assessments, bioanalytical method development, and formulation R&D. These services are crucial for ensuring that compounds are safe and effective before proceeding to human trials.
Services including medical writing, clinical monitoring, regulatory affairs consultations, data management and statistical analysis, decentralized clinical trials, clinical development strategy planning, site management, medical device/in vitro diagnostics support, multi-region clinical trial execution, and vaccine trial management. This wide array of services is designed to manage all aspects of clinical trials, ensuring efficient and regulatory-compliant study conduct.
Tigermed offers medical imaging services which play a critical role in clinical trials by providing precise and reliable data for efficacy and safety assessments, utilizing advanced imaging technologies.
Monitoring and reporting drug safety outcomes to ensure the welfare of trial participants and compliance with global regulatory requirements are essential services that Tigermed excels in.
Ensuring that all operational aspects of a trial or pharmaceutical manufacturing comply with Good Manufacturing Practice (GMP) standards and other quality assurances is a key service offered by Tigermed, bolstering the credibility and reliability of its clients' products.
Centralized laboratory services are provided to ensure consistent and accurate testing outcomes across study sites, crucial for multi-regional clinical trials.
Comprehensive services aimed at the post-approval phase, including site identification, central monitoring, and management, catering to the ongoing research needs post-product launch.
Tigermed also provides a suite of other critical support services such as patient recruitment, investment management, medical registration, pharmaceuticals and regulations consulting, drug safety monitoring, bioequivalence studies, and third-party training programs. These services are designed to supplement and enhance the main product development pathways, ensuring holistic support for clients throughout the pharmaceutical development lifecycle.